MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2022)
MindWalk Holdings (HYFT) posted quarterly Non Operating Interest Expenses of $241.81 for Q3 2022, down 99.82% year-over-year from $132679.2 in Q3 2021, and down 99.96% quarter-over-quarter from $583805.8 in Q2 2022.
MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2022) Analysis & Trends
MindWalk Holdings (HYFT) has reported Non Operating Interest Expenses for 3 consecutive years, with $241.81 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non Operating Interest Expenses fell 99.82% year-over-year to $241.81; the TTM figure through Jul 2022 stood at $584431.3 (down 8.98% YoY), while the FY2022 annual figure was $584270.8, up 10.59% from the prior year.
- Non Operating Interest Expenses fell to $241.81 in Q3 2022 per HYFT's latest filing, from $583805.8 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $583805.8 in Q2 2022 and bottomed at $180.14 in Q1 2022.
- Historically, Non Operating Interest Expenses has averaged $138961.6 across 3 years, with a median of $132679.2 in 2021.
- On a YoY basis, Non Operating Interest Expenses climbed as much as 449.75% in 2021 and fell as far as 99.89% in 2021.
- MindWalk Holdings' Non Operating Interest Expenses stood at $193620.3 in 2020, then sank by 99.89% to $203.63 in 2021, then climbed by 18.75% to $241.81 in 2022.
- Business Quant data shows HYFT's Non Operating Interest Expenses at $241.81 in Q3 2022, $583805.8 in Q2 2022, and $180.14 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2022 | 241.81 |
| Apr 30, 2022 | 583,805.75 |
| Jan 31, 2022 | 180.14 |
| Oct 31, 2021 | 203.63 |
| Jul 31, 2021 | 132,679.23 |
| Apr 30, 2021 | 147,891.85 |
| Jan 31, 2021 | 167,897.03 |
| Oct 31, 2020 | 193,620.32 |
| Jul 31, 2020 | 24,134.34 |